Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer

Background An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional t...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 16; no. 1; p. 102
Main Authors:	Schmid, Gabriel, Notaro, Sara, Reimer, Daniel, Abdel-Azim, Samira, Duggan-Peer, Michaela, Holly, Jessica, Fiegl, Heidi, Rössler, Julia, Wiedemair, Annemarie, Concin, Nicole, Altevogt, Peter, Marth, Christian, Zeimet, Alain Gustave
Format:	Journal Article
Language:	English
Published:	London BioMed Central 15.02.2016 BioMed Central Ltd Springer Nature B.V
Subjects:	Aged Analysis Biomedical and Life Sciences Biomedicine Cancer Research DNA Methylation - genetics Female Gene expression Gene Expression Regulation, Neoplastic - genetics Gene Silencing Health Promotion and Disease Prevention Humans Medicine/Public Health Methylation MicroRNAs - analysis MicroRNAs - genetics MicroRNAs - metabolism Middle Aged Oncology Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - mortality Ovary - chemistry Ovary - metabolism Promoter Regions, Genetic - genetics Research Article Risk factors Surgical Oncology Survival Analysis Tissue Array Analysis Translational oncology Epigenetics Promotor hypermethylation Gene-silencing miR-34a Ovarian cancer
ISSN:	1471-2407, 1471-2407
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes. Methods One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique. Results Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium ( p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers ( p = 0.037), in p53 mutated as compared to p53 wild type cancers ( p = 0.003) and in high grade compared to in low grade cancers ( p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS ( p = 0.039) and OS ( p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis ( p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I ( p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples ( p = 0.05). Conclusion We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.
AbstractList	An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes. One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique. Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium (p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS (p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples (p = 0.05). We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer. Background An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes. Methods One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique. Results Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium ( p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers ( p = 0.037), in p53 mutated as compared to p53 wild type cancers ( p = 0.003) and in high grade compared to in low grade cancers ( p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS ( p = 0.039) and OS ( p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis ( p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I ( p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples ( p = 0.05). Conclusion We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer. An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes.BACKGROUNDAn increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes.One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique.METHODSOne hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique.Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium (p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS (p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples (p = 0.05).RESULTSSignificantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium (p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS (p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples (p = 0.05).We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.CONCLUSIONWe demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.
ArticleNumber	102
Audience	Academic
Author	Fiegl, Heidi Notaro, Sara Rössler, Julia Schmid, Gabriel Altevogt, Peter Wiedemair, Annemarie Zeimet, Alain Gustave Holly, Jessica Reimer, Daniel Concin, Nicole Duggan-Peer, Michaela Abdel-Azim, Samira Marth, Christian
Author_xml	– sequence: 1 givenname: Gabriel surname: Schmid fullname: Schmid, Gabriel organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 2 givenname: Sara surname: Notaro fullname: Notaro, Sara organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Department of Gynecology and Obstetrics, University of Brescia – sequence: 3 givenname: Daniel surname: Reimer fullname: Reimer, Daniel organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 4 givenname: Samira surname: Abdel-Azim fullname: Abdel-Azim, Samira organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 5 givenname: Michaela surname: Duggan-Peer fullname: Duggan-Peer, Michaela organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 6 givenname: Jessica surname: Holly fullname: Holly, Jessica organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 7 givenname: Heidi surname: Fiegl fullname: Fiegl, Heidi organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 8 givenname: Julia surname: Rössler fullname: Rössler, Julia organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 9 givenname: Annemarie surname: Wiedemair fullname: Wiedemair, Annemarie organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 10 givenname: Nicole surname: Concin fullname: Concin, Nicole organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 11 givenname: Peter surname: Altevogt fullname: Altevogt, Peter organization: Skin Cancer Unit, German Cancer Research Center (DKFZ), Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg – sequence: 12 givenname: Christian surname: Marth fullname: Marth, Christian organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck – sequence: 13 givenname: Alain Gustave surname: Zeimet fullname: Zeimet, Alain Gustave email: alain.zeimet@uki.at organization: Department of Obstetrics and Gynaecology, Medical University of Innsbruck
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26879132$$D View this record in MEDLINE/PubMed
BookMark	eNp9kl9r1TAYxotM3B_9AN5IQRC96Oybpml6I4wxdTAQpl6HNH17mpEmxyQdO9_e1LPpOUMlFwl5f8-T5M1znB1YZzHLXkJ5CsDZ-wCE87oogRUEqrogT7IjoA0UhJbNwc76MDsO4aYsoeElf5YdEsabFipylN1c3K09hqCdzaXt87V3k4vO5-NmjX7COG6MjEvVDfmkr4uKylzbPI6Y30qv3RzyUYfojFtpJU0e5i4maVh4txDS5kpahf559nSQJuCL-_kk-_7x4tv55-Lqy6fL87OrQjHGY9EPAyOSdLysWkoH1vVKSQU147IklFSA2HY4tMihx6HqmGLQEyW7tic95VidZB-2vuu5m7BXaKOXRqy9nqTfCCe12K9YPYqVuxW0qSlnkAze3ht492PGEMWkg0JjpMX0XgENq1tCCF_Q14_QGzd7m56XqKZKTQbO_1AraVBoO7h0rlpMxRmtK94AVDRRp3-h0uhx0ir9_KDT_p7g3Z4gMRHv4krOIYjLr9f77JsddkRp4hicmZevDfvgq93u_W7bQ2QS0GwB5V0IHgehdPwVkXRdbQSUYgmn2IZTpHCKJZxiUcIj5YP5_zRkqwmJtSv0Ow3-p-gn5w312A
CitedBy_id	crossref_primary_10_3390_pathogens8040290 crossref_primary_10_1038_s41419_023_06064_9 crossref_primary_10_3892_etm_2018_5920 crossref_primary_10_3390_cancers13051137 crossref_primary_10_3389_fonc_2025_1499163 crossref_primary_10_1017_erm_2023_7 crossref_primary_10_3892_mco_2019_1800 crossref_primary_10_1016_j_jgg_2018_03_001 crossref_primary_10_1016_j_jbiotec_2019_04_003 crossref_primary_10_1016_j_jogoh_2021_102092 crossref_primary_10_3390_ijms23052736 crossref_primary_10_1038_s41389_020_0206_3 crossref_primary_10_3389_fonc_2022_978603 crossref_primary_10_1136_ijgc_2019_000832 crossref_primary_10_3390_ijms241310859 crossref_primary_10_1016_j_jddst_2020_101687 crossref_primary_10_1080_15384101_2022_2087755 crossref_primary_10_1016_j_arr_2016_11_008 crossref_primary_10_3389_fonc_2020_581007 crossref_primary_10_3892_mmr_2018_9182 crossref_primary_10_1016_j_lfs_2020_118871 crossref_primary_10_3389_fphar_2018_00082 crossref_primary_10_3389_fonc_2022_985897 crossref_primary_10_4103_JCOT_JCOT_15_24 crossref_primary_10_1016_j_gene_2018_04_005 crossref_primary_10_1134_S0006297917050017 crossref_primary_10_3389_fonc_2020_00233 crossref_primary_10_1089_dna_2020_6024 crossref_primary_10_1016_j_prp_2024_155656 crossref_primary_10_3390_biom11070998 crossref_primary_10_3390_ijms20040861 crossref_primary_10_1177_03000605211016390 crossref_primary_10_3892_ijmm_2022_5148 crossref_primary_10_1016_j_biopha_2021_111528 crossref_primary_10_1371_journal_pone_0252401 crossref_primary_10_1186_s13046_019_1059_5 crossref_primary_10_1016_j_canlet_2024_217357 crossref_primary_10_3390_ijms21051723 crossref_primary_10_3389_fonc_2020_01152 crossref_primary_10_3892_ijo_2024_5650 crossref_primary_10_1038_s41598_023_45317_7 crossref_primary_10_1371_journal_pone_0320855 crossref_primary_10_1134_S0026893318050102 crossref_primary_10_3390_diagnostics11020344 crossref_primary_10_1016_j_lfs_2022_121361 crossref_primary_10_1038_srep33936 crossref_primary_10_1097_MPA_0000000000001542 crossref_primary_10_3390_ijms24076116 crossref_primary_10_1007_s00018_020_03634_4 crossref_primary_10_1038_s41598_022_21864_3 crossref_primary_10_1371_journal_pone_0213494 crossref_primary_10_1186_s13045_016_0387_6 crossref_primary_10_1038_s41419_019_1604_3 crossref_primary_10_1515_pteridines_2020_0006 crossref_primary_10_1016_j_ijbiomac_2018_06_036 crossref_primary_10_1161_CIRCULATIONAHA_117_031258 crossref_primary_10_1016_j_cancergen_2020_08_005 crossref_primary_10_1016_j_humgen_2023_201218 crossref_primary_10_3389_fcell_2019_00182
Cites_doi	10.1038/nm.2284 10.1038/sj.onc.1210293 10.1158/0008-5472.CAN-08-3913 10.1016/j.cub.2007.06.068 10.3892/mmr.2015.4110 10.1111/bjh.12157 10.1038/onc.2011.119 10.1093/annonc/mdr568 10.1038/nm0211-162 10.4161/cc.6.13.4436 10.1007/s13277-015-3445-8 10.1016/S1470-2045(03)01139-2 10.1158/1078-0432.CCR-05-0755 10.18632/oncotarget.1552 10.1158/0008-5472.CAN-09-3551 10.1093/jnci/djt144 10.1016/j.molcel.2007.05.010 10.1038/nrc1840 10.2165/00003495-200868060-00004 10.1158/1078-0432.CCR-06-0780 10.1007/s00428-010-1030-5
ContentType	Journal Article
Copyright	Schmid et al. 2016 COPYRIGHT 2016 BioMed Central Ltd. Copyright BioMed Central 2016
Copyright_xml	– notice: Schmid et al. 2016 – notice: COPYRIGHT 2016 BioMed Central Ltd. – notice: Copyright BioMed Central 2016
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1186/s12885-016-2135-2
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1471-2407
ExternalDocumentID	PMC4754861 3986587201 A453871134 26879132 10_1186_s12885_016_2135_2
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- 0R~ 23N 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c668t-dff62a2b803944f6bdccac1568a024231ee9bef9e81def3b6c61d2cab9d2d48e3
IEDL.DBID	RSV
ISICitedReferencesCount	71
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000370014400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1471-2407
IngestDate	Tue Nov 04 02:02:17 EST 2025 Thu Oct 02 11:24:17 EDT 2025 Mon Oct 06 18:37:07 EDT 2025 Tue Nov 11 10:22:48 EST 2025 Tue Nov 04 18:03:53 EST 2025 Thu Nov 13 14:45:58 EST 2025 Thu May 22 20:58:57 EDT 2025 Thu Apr 03 07:02:21 EDT 2025 Sat Nov 29 04:29:39 EST 2025 Tue Nov 18 22:14:49 EST 2025 Sat Sep 06 07:24:36 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Epigenetics Promotor hypermethylation Gene-silencing miR-34a Ovarian cancer
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c668t-dff62a2b803944f6bdccac1568a024231ee9bef9e81def3b6c61d2cab9d2d48e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://link.springer.com/10.1186/s12885-016-2135-2
PMID	26879132
PQID	1773791188
PQPubID	44074
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_4754861 proquest_miscellaneous_1765922281 proquest_journals_1773791188 gale_infotracmisc_A453871134 gale_infotracacademiconefile_A453871134 gale_incontextgauss_ISR_A453871134 gale_healthsolutions_A453871134 pubmed_primary_26879132 crossref_citationtrail_10_1186_s12885_016_2135_2 crossref_primary_10_1186_s12885_016_2135_2 springer_journals_10_1186_s12885_016_2135_2
PublicationCentury	2000
PublicationDate	2016-02-15
PublicationDateYYYYMMDD	2016-02-15
PublicationDate_xml	– month: 02 year: 2016 text: 2016-02-15 day: 15
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	BMC cancer
PublicationTitleAbbrev	BMC Cancer
PublicationTitleAlternate	BMC Cancer
PublicationYear	2016
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V
References	A Esquela-Kerscher (2135_CR6) 2006; 6 C Welch (2135_CR19) 2007; 26 CH Lawrie (2135_CR5) 2013; 160 B Kumar (2135_CR9) 2012 M Markman (2135_CR4) 2008; 68 D Takai (2135_CR15) 2003; 3 U Schirmer (2135_CR13) 2014; 5 V Tarasov (2135_CR20) 2007; 6 2135_CR24 MS Wicha (2135_CR11) 2011; 17 2135_CR16 2135_CR17 RJ Kurman (2135_CR2) 2009; 69 2135_CR18 TC Chang (2135_CR8) 2007; 26 B Wei (2135_CR22) 2015; 12 D Reimer (2135_CR12) 2011; 30 C Liu (2135_CR10) 2011; 17 D Reimer (2135_CR14) 2007; 13 GT Bommer (2135_CR7) 2007; 17 AG Zeimet (2135_CR21) 2003; 4 M Shih Ie (2135_CR1) 2005; 11 M Shih Ie (2135_CR3) 2004; 164 RSX Li (2135_CR23) 2015; 36 21297608 - Nat Med. 2011 Feb;17(2):162-4 12850192 - Lancet Oncol. 2003 Jul;4(7):415-22 12954087 - In Silico Biol. 2003;3(3):235-40 17554199 - Cell Cycle. 2007 Jul 1;6(13):1586-93 21240262 - Nat Med. 2011 Feb;17(2):211-5 21516127 - Oncogene. 2011 Sep 22;30(38):4038-49 23205669 - Br J Haematol. 2013 Mar;160(5):571-81 19383911 - Cancer Res. 2009 May 1;69(9):4036-42 16243797 - Clin Cancer Res. 2005 Oct 15;11(20):7273-9 24497324 - Oncotarget. 2014 Jan 30;5(2):462-72 26238271 - Mol Med Rep. 2015 Oct;12(4):5255-61 16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69 17297439 - Oncogene. 2007 Jul 26;26(34):5017-22 20460525 - Cancer Res. 2010 Jun 1;70(11):4613-23 22629428 - PLoS One. 2012;7(5):e37601 22228447 - Ann Oncol. 2012 Jul;23(7):1795-802 18416585 - Drugs. 2008;68(6):771-89 17540599 - Mol Cell. 2007 Jun 8;26(5):745-52 25895459 - Tumour Biol. 2015 Sep;36(9):7277-83 15111296 - Am J Pathol. 2004 May;164(5):1511-8 17656095 - Curr Biol. 2007 Aug 7;17(15):1298-307 21225432 - Virchows Arch. 2011 Mar;458(3):313-22 17200349 - Clin Cancer Res. 2007 Jan 1;13(1):144-51 23781004 - J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50
References_xml	– volume: 17 start-page: 211 issue: 2 year: 2011 ident: 2135_CR10 publication-title: Nat Med doi: 10.1038/nm.2284 – volume: 164 start-page: 1511 year: 2004 ident: 2135_CR3 publication-title: Ovarian Tumorigenesis – volume: 26 start-page: 5017 year: 2007 ident: 2135_CR19 publication-title: Oncogene doi: 10.1038/sj.onc.1210293 – volume: 69 start-page: 4036 issue: 9 year: 2009 ident: 2135_CR2 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3913 – volume: 17 start-page: 1298 year: 2007 ident: 2135_CR7 publication-title: Curr Biol doi: 10.1016/j.cub.2007.06.068 – volume-title: Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis year: 2012 ident: 2135_CR9 – volume: 12 start-page: 5255 issue: 4 year: 2015 ident: 2135_CR22 publication-title: Mol Med Rep doi: 10.3892/mmr.2015.4110 – volume: 160 start-page: 571 year: 2013 ident: 2135_CR5 publication-title: Br J Haematol doi: 10.1111/bjh.12157 – volume: 30 start-page: 4038 year: 2011 ident: 2135_CR12 publication-title: Oncogene doi: 10.1038/onc.2011.119 – ident: 2135_CR18 doi: 10.1093/annonc/mdr568 – volume: 17 start-page: 162 year: 2011 ident: 2135_CR11 publication-title: Nat Med doi: 10.1038/nm0211-162 – volume: 6 start-page: 1586 year: 2007 ident: 2135_CR20 publication-title: Cell Cycle doi: 10.4161/cc.6.13.4436 – volume: 36 start-page: 7277 issue: 9 year: 2015 ident: 2135_CR23 publication-title: Tumour Biol doi: 10.1007/s13277-015-3445-8 – volume: 4 start-page: 415 issue: 7 year: 2003 ident: 2135_CR21 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(03)01139-2 – volume: 11 start-page: 7273 year: 2005 ident: 2135_CR1 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0755 – volume: 5 start-page: 462 issue: 2 year: 2014 ident: 2135_CR13 publication-title: Oncotarget doi: 10.18632/oncotarget.1552 – ident: 2135_CR16 doi: 10.1158/0008-5472.CAN-09-3551 – ident: 2135_CR17 doi: 10.1093/jnci/djt144 – volume: 26 start-page: 745 year: 2007 ident: 2135_CR8 publication-title: Mol Cell doi: 10.1016/j.molcel.2007.05.010 – volume: 3 start-page: 235 year: 2003 ident: 2135_CR15 publication-title: In Silico Biol – volume: 6 start-page: 259 year: 2006 ident: 2135_CR6 publication-title: Nat Rev Cancer doi: 10.1038/nrc1840 – volume: 68 start-page: 771 year: 2008 ident: 2135_CR4 publication-title: Drugs doi: 10.2165/00003495-200868060-00004 – volume: 13 start-page: 144 year: 2007 ident: 2135_CR14 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0780 – ident: 2135_CR24 doi: 10.1007/s00428-010-1030-5 – reference: 21516127 - Oncogene. 2011 Sep 22;30(38):4038-49 – reference: 20460525 - Cancer Res. 2010 Jun 1;70(11):4613-23 – reference: 17200349 - Clin Cancer Res. 2007 Jan 1;13(1):144-51 – reference: 24497324 - Oncotarget. 2014 Jan 30;5(2):462-72 – reference: 18416585 - Drugs. 2008;68(6):771-89 – reference: 17297439 - Oncogene. 2007 Jul 26;26(34):5017-22 – reference: 21297608 - Nat Med. 2011 Feb;17(2):162-4 – reference: 17554199 - Cell Cycle. 2007 Jul 1;6(13):1586-93 – reference: 26238271 - Mol Med Rep. 2015 Oct;12(4):5255-61 – reference: 17656095 - Curr Biol. 2007 Aug 7;17(15):1298-307 – reference: 19383911 - Cancer Res. 2009 May 1;69(9):4036-42 – reference: 23205669 - Br J Haematol. 2013 Mar;160(5):571-81 – reference: 23781004 - J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50 – reference: 21240262 - Nat Med. 2011 Feb;17(2):211-5 – reference: 16243797 - Clin Cancer Res. 2005 Oct 15;11(20):7273-9 – reference: 22228447 - Ann Oncol. 2012 Jul;23(7):1795-802 – reference: 12850192 - Lancet Oncol. 2003 Jul;4(7):415-22 – reference: 16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69 – reference: 12954087 - In Silico Biol. 2003;3(3):235-40 – reference: 25895459 - Tumour Biol. 2015 Sep;36(9):7277-83 – reference: 15111296 - Am J Pathol. 2004 May;164(5):1511-8 – reference: 22629428 - PLoS One. 2012;7(5):e37601 – reference: 21225432 - Virchows Arch. 2011 Mar;458(3):313-22 – reference: 17540599 - Mol Cell. 2007 Jun 8;26(5):745-52
SSID	ssj0017808
Score	2.4162903
Snippet	Background An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In... An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian...
SourceID	pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	102
SubjectTerms	Aged Analysis Biomedical and Life Sciences Biomedicine Cancer Research DNA Methylation - genetics Female Gene expression Gene Expression Regulation, Neoplastic - genetics Gene Silencing Health Promotion and Disease Prevention Humans Medicine/Public Health Methylation MicroRNAs - analysis MicroRNAs - genetics MicroRNAs - metabolism Middle Aged Oncology Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - mortality Ovary - chemistry Ovary - metabolism Promoter Regions, Genetic - genetics Research Article Risk factors Surgical Oncology Survival Analysis Tissue Array Analysis Translational oncology
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEA96ivji98fqqVEEQQnXJtkkfZJD7lDQQ06FfStpPrwVbdft7qH_vTNttl4XvBef80tJOl-ZzGSGkOcyZBYMX2RVDI5J4RQz0mcsq5zxmS5s4bs6s-_10ZGZzYqP6cKtTWmVG53YKWrfOLwj38u1Fhok05jXi58Mu0ZhdDW10LhILmHbbORzPRscrlybzKRIZm7UXgu62GCqmmI8F1PGR7ZoWyOfMUnb6ZJbMdPOFB1e_99N3CDX0iGU7vdcc5NcCPUtcuVDCrPfJt8OfqX82Jra2tNFl7PXLOkJeK1LbDr9u0-ho02kP-bHTEhL5zWFwyQ9Bee7Wbe0K2ScFCtt1xXe9baIbxBha-qQ35Z3yJfDg89v3rLUlIE5pcyK-RgVt7wyGT6pjarywAMOvEBj0dyLPISiCrEIcBAOUVTKqdxzZ6vCcy9NEHfJTt3U4T6h6HzawjkTvZXcRiu1FRhntMU06IpPSLYhT-lSxXJsnPG97DwXo8qeoiVmqSFFS5jycpiy6Mt1nAd-gjQv-xeng6iX-xKsgM5zISfkWYfAQhk1ZuJ8teu2Ld99Oh6BXiRQbGB58Df6hw2wSaytNULujpAgyW48vOGaMmmStvzLMhPydBjGmZgdVwegKGAwOM65ySfkXs-rw-65MjBdwGb1iIsHANYXH4_U85OuzrjU4M4q-OarDb-fWda_fuqD8zfxkFzlKIDYUme6S3ZWy3V4RC6709W8XT7uxPcP_yZOvw priority: 102 providerName: ProQuest
Title	Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
URI	https://link.springer.com/article/10.1186/s12885-016-2135-2 https://www.ncbi.nlm.nih.gov/pubmed/26879132 https://www.proquest.com/docview/1773791188 https://www.proquest.com/docview/1765922281 https://pubmed.ncbi.nlm.nih.gov/PMC4754861
Volume	16
WOSCitedRecordID	wos000370014400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEA96J3JffHuunmsUQVCKbdpN0o-n7OGBtyx7KuunkKaJt6Lt0e4e-t87kz64Lirol0LJLyWPeWQ6kxlCnic21KD4XJA5a4IkNjyQSR4GYWZkHopUp7nPM_tezGZyuUzn7T3uuot271ySXlJ7tpb8dQ2SVGKgGQ9YFE8CkLu7oO0k1mtYnH7qXQdChrJ1X_6220ABbYvhS3poO0Zyy1Hq9c_Rzf8a-S1yoz1u0sOGPm6TK7a4Q66ftA71u-Tr9EcbCVtQXeT03EfnlRU9A_u0wvLSP5tgOVo6-n21COJE01VB4dhIL8DMLjc19SmLWxFK602Gf3VrxJeI0AU1SFnVPfLxaPrh7bugLb8QGM7lOsid40yzTIZ4edbxLIfdNmDvSY2KPY6sTTPrUgtHXuvijBse5czoLM1Znkgb3yc7RVnYB4SimalTY6TLdcK004nQMXoUdTqxImMjEnZ7okybmxxLZHxT3kaRXDVrqDAeDddQQZeXfZfzJjHH38BPcKNVc7e0Z2p1mIC8F1EUJyPyzCMwJUaBMTdf9Kau1fHpYgB60YJcCcOD1WiuMMAkMYvWAHkwQALPmmFzR3GqlRm1ioSIBegeKUfkad-MPTEOrrCwo4BBNzhjMhqR_YZA-9kzLqF7DJMVA9LtAZhJfNhSrM58RvFEgOHK4ZuvOgK-NKw_LerDf0I_InsMOQBr6UwOyM662tjH5Jq5WK_qakyuiqXwTzkmu2-ms_li7H-PwNv8-GT-eeyZ_BfuMUpE
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF92OhUINASKCoiZO1nQNCFbTqqtsKlVbaW3D8oIsgWZLdQv8Uv5GZvGhWorceOPtzlHHm4Yk_zxDyIrK-gsDnvNRZ7UWh5p6MjO_5qZbGF7GKTVVndiz29-VkEn9cIb_buzBIq2x9YuWoTa7xH_lGIEQowDKlfDf74WHXKDxdbVto1Gqxa09_QspWvh19gO_7krHtrcP3O17TVcDTnMu5Z5zjTLFU-ngn1PHUgBAa0hipMF6FgbVxal1sYSdnXZhyzQPDtEpjw0wkbQjPvUQugx8XmOyJSZfgBUL6sjk5DSTfKMH3S6TGcY8F4dBjvdi3HAHOhMBleubSGW0V-rZv_m-LdovcaDbZdLO2ittkxWZ3yNW9hkZwl3zd-tXwfzOqMkNnFScxL-gxZOUFNtU-rSmCNHf0-_TACyNFpxmFzTI9UQXShmlVqLkJHLRcpPgvu0R8jgiVUY32VNwjRxci6X2ymuWZfUgoJtcq1lo6oyKmnIqECvEcVcVDK1I2IH6rDoluKrJjY5BvSZWZSZ7UGpQgCw81KIEpr7sps7ocyXngddSxpL5R27myZDOCKCeCIIwG5HmFwEIgGTKNvqhFWSajTwc90KsG5HJ4PViN-uIGCIm1w3rItR4SPJXuD7damjSeskz-quiAPOuGcSay_zILXxQwePjPmAwG5EFtG530jEuYHoKwomc1HQDrp_dHsulxVUc9EpCuc3jmm9a-zrzWvxb10flCrJNrO4d742Q82t99TK4zNH5sHzRcI6vzYmGfkCv6ZD4ti6eV66Dk80Wb3R9bY69d
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbQQBMv3C-FwQxCQgJFSxzXdh4nWMXEqKYN0N4sxxdWBE7VtBP8e85J0mipAAnx7M9VbJ-LT8_ncwh5wX1qwPGFpAzeJjy3IlHcpUlaWuVSWZjCNXVmj-R0qs7OiuOuz2m9ZruvU5Ltmwas0hSXe3MXWhVXYq8Gq6qQdCYSluXjBGzwVY48egzXTz_3aQSpUtWlMn87beCMNk3yJZ-0yZfcSJo2vmhy879XcYvc6K6hdL-Vm9vkio93yPaHLtF-l3w9-NExZCM10dF5w9qrFvQc4tYFtp3-2ZLoaBXo99lJknNDZ5HCdZJeQPhdrWralDLuTCutVyX-21sjvkKEidSixC3ukU-Tg49v3iVdW4bECqGWiQtBMMNKleKj2iBKB1JgIQ5UBh1-nnlflD4UHq7CPuSlsCJzzJqycMxx5fP7ZCtW0T8kFMNPU1irgjOcmWC4NDlmGk0x9rJkI5Kuz0fbrmY5ts74ppvYRQnd7qFGnhruoYYpr_op87Zgx9_Au3joun1z2iu73ufgB2SW5XxEnjcILJURkYvzxazqWh-engxALztQqODzYDfapw2wSKyuNUDuDJCgy3Y4vJY-3dmSWmdS5hJ8klIj8qwfxpnIj4seThQwmB5nTGUj8qAV1n71TCiYnsNi5UCMewBWGB-OxNl5U2mcSwhoBfzm67UwX_qsP23qo39C75Lt47cTfXQ4ff-YXGeoDNhuZ7xDtpaLlX9CrtmL5axePG00-xd0DE_8
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+and+promotor+hypermethylation+of+miR-34a+in+the+various+histological+subtypes+of+ovarian+cancer&rft.jtitle=BMC+cancer&rft.au=Schmid%2C+Gabriel&rft.au=Notaro%2C+Sara&rft.au=Reimer%2C+Daniel&rft.au=Abdel-Azim%2C+Samira&rft.date=2016-02-15&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-016-2135-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12885_016_2135_2
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon